Ghost Tree Capital
Latest statistics and disclosures from Ghost Tree Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, Biohaven, SRPT, NVO, BPMC, and represent 26.61% of Ghost Tree Capital's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$30M), Biohaven (+$17M), NVO (+$13M), BPMC (+$9.3M), SRPT (+$8.1M), JANX (+$6.4M), EWTX (+$5.2M), CRBP, TARS, DYN.
- Started 11 new stock positions in XBI, CAPR, SMMT, AMLX, CRVS, LRMR, EWTX, Biohaven, NVO, ABSI. DYN.
- Reduced shares in these 10 stocks: , BHVN (-$17M), VRDN (-$12M), INSM (-$10M), MLTX (-$8.7M), PCVX (-$8.0M), SLNO (-$7.6M), SYRE (-$5.6M), ASND (-$5.1M), CRNX.
- Sold out of its positions in ACAD, ALNY, ANTX, ARWR, CABA, CYTK, CTMX, ELEV, NTLA, ITCI. KRYS, MGNX, PMVP, PTCT, Rapt Therapeutics, Revance Therapeutics, SGMT, BHVN, WVE.
- Ghost Tree Capital was a net seller of stock by $-21M.
- Ghost Tree Capital has $331M in assets under management (AUM), dropping by 3.67%.
- Central Index Key (CIK): 0001595851
Tip: Access up to 7 years of quarterly data
Positions held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ghost Tree Capital
Ghost Tree Capital holds 52 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 9.0 | $30M | NEW | 300k | 98.80 |
|
| Biohaven Call | 5.3 | $17M | NEW | 349k | 49.97 |
|
| Sarepta Therapeutics (SRPT) | 4.5 | $15M | +118% | 120k | 124.89 |
|
| Novo-nordisk A S Adr (NVO) | 4.0 | $13M | NEW | 110k | 119.07 |
|
| Blueprint Medicines (BPMC) | 3.9 | $13M | +250% | 140k | 92.50 |
|
| Axsome Therapeutics (AXSM) | 3.7 | $12M | -10% | 135k | 89.87 |
|
| Tarsus Pharmaceuticals (TARS) | 3.5 | $12M | +48% | 350k | 32.89 |
|
| Perspective Therapeutics Com New (CATX) | 3.0 | $10M | -18% | 750k | 13.35 |
|
| Cg Oncology (CGON) | 2.8 | $9.4M | -3% | 250k | 37.73 |
|
| Roivant Sciences SHS (ROIV) | 2.8 | $9.2M | -20% | 800k | 11.54 |
|
| Vaxcyte (PCVX) | 2.8 | $9.1M | -46% | 80k | 114.27 |
|
| Insmed Com Par $.01 (INSM) | 2.8 | $9.1M | -52% | 125k | 73.00 |
|
| Viking Therapeutics (VKTX) | 2.7 | $8.9M | +47% | 140k | 63.31 |
|
| Syndax Pharmaceuticals (SNDX) | 2.6 | $8.7M | +28% | 450k | 19.25 |
|
| Janux Therapeutics (JANX) | 2.6 | $8.6M | +280% | 190k | 45.43 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.4 | $7.8M | +117% | 380k | 20.63 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.4 | $7.8M | -39% | 53k | 149.31 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.3 | $7.7M | -37% | 150k | 51.10 |
|
| Soleno Therapeutics (SLNO) | 2.3 | $7.6M | -50% | 150k | 50.49 |
|
| Tg Therapeutics (TGTX) | 2.2 | $7.3M | -38% | 310k | 23.39 |
|
| Rezolute Com New (RZLT) | 2.2 | $7.2M | +3% | 1.5M | 4.85 |
|
| Phathom Pharmaceuticals (PHAT) | 2.0 | $6.8M | -37% | 375k | 18.08 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.0 | $6.5M | -57% | 128k | 50.42 |
|
| Olema Pharmaceuticals (OLMA) | 1.9 | $6.4M | -2% | 535k | 11.94 |
|
| Immunovant (IMVT) | 1.9 | $6.1M | -17% | 215k | 28.51 |
|
| Edgewise Therapeutics (EWTX) | 1.6 | $5.2M | NEW | 195k | 26.69 |
|
| Replimune Group (REPL) | 1.5 | $4.9M | 450k | 10.96 |
|
|
| Bridgebio Pharma (BBIO) | 1.3 | $4.5M | +25% | 175k | 25.46 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.3 | $4.3M | +72% | 2.2M | 2.01 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $4.1M | -32% | 79k | 52.39 |
|
| Annexon (ANNX) | 1.2 | $3.8M | +23% | 650k | 5.92 |
|
| Korro Bio (KRRO) | 1.1 | $3.7M | +10% | 110k | 33.42 |
|
| Dyne Therapeutics (DYN) | 1.1 | $3.6M | NEW | 100k | 35.92 |
|
| Arvinas Ord (ARVN) | 1.1 | $3.6M | +93% | 145k | 24.63 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.9 | $3.1M | 300k | 10.45 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.9 | $3.1M | +17% | 1.4M | 2.29 |
|
| Savara (SVRA) | 0.9 | $3.1M | -31% | 725k | 4.24 |
|
| Tenaya Therapeutics (TNYA) | 0.9 | $2.9M | +11% | 1.5M | 1.93 |
|
| Regenxbio Inc equity us cm (RGNX) | 0.8 | $2.8M | +55% | 265k | 10.49 |
|
| Corvus Pharmaceuticals (CRVS) | 0.8 | $2.6M | NEW | 500k | 5.28 |
|
| Absci Corp (ABSI) | 0.6 | $2.1M | NEW | 550k | 3.82 |
|
| Neurogene (NGNE) | 0.6 | $2.1M | -28% | 50k | 41.96 |
|
| Capricor Therapeutics Com New (CAPR) | 0.6 | $1.9M | NEW | 125k | 15.21 |
|
| Apellis Pharmaceuticals (APLS) | 0.6 | $1.9M | -51% | 65k | 28.84 |
|
| Summit Therapeutics (SMMT) | 0.6 | $1.9M | NEW | 85k | 21.90 |
|
| Spyre Therapeutics Com New (SYRE) | 0.5 | $1.8M | -76% | 60k | 29.41 |
|
| Miragen Therapeutics (VRDN) | 0.5 | $1.7M | -87% | 75k | 22.75 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.5 | $1.6M | 888k | 1.82 |
|
|
| Atyr Pharma Com New (ATYR) | 0.4 | $1.4M | 800k | 1.76 |
|
|
| Larimar Therapeutics (LRMR) | 0.4 | $1.3M | NEW | 200k | 6.55 |
|
| Engene Holdings (ENGN) | 0.3 | $1.1M | -61% | 161k | 6.60 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.3 | $1.1M | NEW | 325k | 3.24 |
|
Past Filings by Ghost Tree Capital
SEC 13F filings are viewable for Ghost Tree Capital going back to 2013
- Ghost Tree Capital 2024 Q3 filed Nov. 14, 2024
- Ghost Tree Capital 2024 Q2 filed Aug. 14, 2024
- Ghost Tree Capital 2024 Q1 filed May 15, 2024
- Ghost Tree Capital 2023 Q4 filed Feb. 14, 2024
- Ghost Tree Capital 2023 Q3 filed Nov. 14, 2023
- Ghost Tree Capital 2023 Q2 filed Aug. 14, 2023
- Ghost Tree Capital 2023 Q1 filed May 15, 2023
- Ghost Tree Capital 2022 Q4 filed Feb. 14, 2023
- Ghost Tree Capital 2022 Q3 filed Nov. 14, 2022
- Ghost Tree Capital 2022 Q2 filed Aug. 15, 2022
- Ghost Tree Capital 2022 Q1 filed May 16, 2022
- Ghost Tree Capital 2021 Q4 filed Feb. 16, 2022
- Ghost Tree Capital 2021 Q3 filed Nov. 15, 2021
- Ghost Tree Capital 2021 Q1 restated filed Aug. 11, 2021
- Ghost Tree Capital 2021 Q2 filed Aug. 11, 2021
- Ghost Tree Capital 2021 Q1 filed May 14, 2021